Windlas Biotech Ltd Quarterly Results
Q4 FY25-26 Results Summary
Revenue
The revenue stands at ₹238.50 crore, reflecting a quarter-on-quarter *(QoQ) increase of 2.32 per cent from ₹233.10 crore. This corresponds to a year-on-year *(YoY) growth of 17.66 per cent.
Operating Profit
Operating Profit stands at ₹25.29 crore, reflecting a quarter-on-quarter *(QoQ) increase of 3.78 per cent from ₹24.37 crore. This corresponds to a year-on-year *(YoY) decline of 1.02 per cent.
PBDT
PBDT stands at ₹28.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.81 per cent from ₹27.67 crore. This corresponds to a year-on-year *(YoY) decline of 3.43 per cent.
Profit Before Tax
Profit Before Tax stands at ₹20.17 crore, reflecting a quarter-on-quarter *(QoQ) increase of 1.00 per cent from ₹19.97 crore. This corresponds to a year-on-year *(YoY) decline of 3.17 per cent.
Net Profit
Net Profit stands at ₹15.99 crore, reflecting a quarter-on-quarter *(QoQ) increase of 6.60 per cent from ₹15.00 crore. This represents a 1.78 per cent year-on-year *(YoY) decline for the same year.
- YoY compares a quarter to the same period last year, and QoQ compares it to the previous quarter.
Market News
Windlas Biotech Ltd Earnings
- YOY
- QOQ
Windlas Biotech Ltd Earning Charts
Revenue from Operations
in ₹ cr
EBITDA
in ₹ cr
Profit before Tax
in ₹ cr
Net Profit
in ₹ cr
Windlas Biotech Ltd Research Reports
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Windlas Biotech Ltd Financial Reports
Windlas Biotech Ltd Stock Prices Compare with Peers
| Company | 1 Day | 1 Week | 1 month | 3 month | 6 month | 1 Year |
|---|---|---|---|---|---|---|
| Windlas Biotech | 5.39% | 3.63% | -4.53% | 9.36% | 4.25% | -11.25% |
| Hester Bios | 13.60% | 17.01% | 29.15% | 38.56% | 30.24% | 19.55% |
| Indoco Remedies | -1.05% | -8.26% | -7.69% | -4.22% | -24.82% | -22.02% |
| NGL Fine Chem | -2.61% | 15.93% | 20.96% | 22.11% | 109.68% | 131.51% |
| Amrutanjan Healt | -0.02% | 1.19% | -3.75% | -5.71% | -18.04% | -23.13% |
| Venus Remedies | 2.34% | 11.47% | 24.05% | 73.12% | 61.23% | 189.54% |
| Syncom Formul. | 0.63% | 12.96% | 13.52% | 24.90% | 2.05% | -27.60% |
Company Info
Company Information
Chairman & Independent Director : Vivek Dhariwal
Whole-time Director : Ashok Kumar Windlass
Managing Director : Hitesh Windlass
Joint Managing Director : Manoj Kumar Windlass
Executive Director : Pawan Kumar Sharma
Non-Executive & Non-Independent Director : Prachi Jain Windlass
Non Executive & Independent Director : Gaurav Gulati
Company Sec. & Compli. Officer : Ananta Narayan Panda
Additional Director : Tarashree Singhal